These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Inhibition of cytochrome P450 2E1 induces an increase in extracellular dopamine in rat substantia nigra: a new metabolic pathway? Nissbrandt H; Bergquist F; Jonason J; Engberg G Synapse; 2001 Jun; 40(4):294-301. PubMed ID: 11309845 [TBL] [Abstract][Full Text] [Related]
6. Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility. Hofele K; Sedelis M; Auburger GW; Morgan S; Huston JP; Schwarting RK Exp Neurol; 2001 Mar; 168(1):116-22. PubMed ID: 11170726 [TBL] [Abstract][Full Text] [Related]
7. Diethyldithiocarbamate causes nigral cell loss and dopamine depletion with nontoxic doses of MPTP. Walters TL; Irwin I; Delfani K; Langston JW; Janson AM Exp Neurol; 1999 Mar; 156(1):62-70. PubMed ID: 10192777 [TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease. Schmidt N; Ferger B Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221 [TBL] [Abstract][Full Text] [Related]
9. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease. Liu LX; Chen WF; Xie JX; Wong MS Neurosci Res; 2008 Feb; 60(2):156-61. PubMed ID: 18054104 [TBL] [Abstract][Full Text] [Related]
10. MPTP treatment in mice does not transmit and cause Parkinsonian neurotoxicity in non-treated cagemates through close contact. Lau YS; Novikova L; Roels C Neurosci Res; 2005 Aug; 52(4):371-8. PubMed ID: 15936837 [TBL] [Abstract][Full Text] [Related]
11. Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration. Drolet RE; Behrouz B; Lookingland KJ; Goudreau JL Neurotoxicology; 2004 Sep; 25(5):761-9. PubMed ID: 15288507 [TBL] [Abstract][Full Text] [Related]
12. Effects of monoamine oxidase inhibitors on the diethyldithiocarbamate-induced enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in C57BL/6 mice. Takahata K; Shimazu S; Yoneda F; Ogawa M; Iida Y; Saji H J Neural Transm (Vienna); 2003 Aug; 110(8):859-69. PubMed ID: 12898342 [TBL] [Abstract][Full Text] [Related]
13. Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration. Holmer HK; Keyghobadi M; Moore C; Menashe RA; Meshul CK Synapse; 2005 Aug; 57(2):100-12. PubMed ID: 15906381 [TBL] [Abstract][Full Text] [Related]
14. Effects of testosterone upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system of C57/B1 mice. Dluzen DE Brain Res; 1996 Apr; 715(1-2):113-8. PubMed ID: 8739629 [TBL] [Abstract][Full Text] [Related]
15. Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice. Muthane U; Ramsay KA; Jiang H; Jackson-Lewis V; Donaldson D; Fernando S; Ferreira M; Przedborski S Exp Neurol; 1994 Apr; 126(2):195-204. PubMed ID: 7925820 [TBL] [Abstract][Full Text] [Related]
16. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease. Novikova L; Garris BL; Garris DR; Lau YS Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572 [TBL] [Abstract][Full Text] [Related]
18. In brown Norway rats, MPP+ is accumulated in the nigrostriatal dopaminergic terminals but it is not neurotoxic: a model of natural resistance to MPTP toxicity. Zuddas A; Fascetti F; Corsini GU; Piccardi MP Exp Neurol; 1994 May; 127(1):54-61. PubMed ID: 8200437 [TBL] [Abstract][Full Text] [Related]
19. Vigilance states in a parkinsonian model, the MPTP mouse. Monaca C; Laloux C; Jacquesson JM; Gelé P; Maréchal X; Bordet R; Destée A; Derambure P Eur J Neurosci; 2004 Nov; 20(9):2474-8. PubMed ID: 15525288 [TBL] [Abstract][Full Text] [Related]